Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 1, 2007, Pages 9-15

  Bláha, Milan ^a   Cermanová, Melanie ^a   Bláha, Vladimír ^a   Blažek, Martin ^a   Malý, Jaroslav ^a   Široký, Oldřich ^a   Solichová, Dagmar ^a   Filip, Stanislav ^a   Řeháček, Vít ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Adverse events; Atherosclerosis; Familial hyperlipoproteinemia; LDL apheresis; Side effects

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ADVERSE OUTCOME; APHERESIS; ARTICLE; BLOOD PRESSURE FLUCTUATION; BLOOD SAMPLING; BRADYCARDIA; CENTRIFUGATION; CHILL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HEMATOMA; HUMAN; HYPERLIPOPROTEINEMIA; HYPOTENSION; IMMUNOADSORPTION; INCIDENCE; LONG TERM CARE; MALAISE; MALE; MEDICAL INSTRUMENTATION; MENTAL INSTABILITY; MUSCLE TONE; NAUSEA; PALLIATIVE THERAPY; PARESTHESIA; PRIORITY JOURNAL; SAFETY; SINUS BRADYCARDIA; SYNCOPE; TREATMENT RESPONSE; WEAKNESS;

ADOLESCENT; ADSORPTION; ADULT; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; MALE; MIDDLE AGED; PLASMAPHERESIS;

EID: 33846995093     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00450.x     Document Type: Article

References (22)

1. Bambauer R. Is lipoprotein (a) - apheresis useful? Ther Apher 2005;9:142-7.
2. Schuff-Werner P. Clinical long-term results of H.E.L.P-apheresis. Z Kardiol 2003;92:III28-9.
3. Splendiani G, Cipriani S, Passalacqua S et al. Plasma perfusion on tryptophan columns can improve the clinical outcome of patients affected with myasthenia gravis. Artif Cell-Blood Substit Immobil Biotechnol 2003;31:69-79.
4. Seidel D, Armstrong VW, Schuff-Werner P. The HELP-LDL-Apheresis Multicentre Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering affects during the first 12 month. Eur J Clin Invest 1991;21:375-83.5.
5. Bambauer R, Schiel R, Latza R. Low-density lipoprotein apheresis: an overview. Ther Apher Dial 2003;7:391-6.
6. Gordon BR, Stein E, Jones P, Illingworth DR. Indications for low-density lipoprotein apheresis. Am J Cardiol 1994;74:1109-12.
7. Bláha V, Zadák Z, Bláha M et al. Recommended indication criteria for LDL-apheresis treatment (in Czech). Cas Lek Ces 1998;137:424-9.
8. Bláha V, Zadák Z, Bláha M, Havel E, Vyroubal P, Malý J. LDL-apheresis: history and current practice in Czech Republic (in Czech). Kapit Kardiol 2001;3:72-6.
9. Bláha V, Solichová D, Zadák Z et al. Immunoadsorption LDL-apheresis in the treatment of severe hypercholesterolemia (in Czech). In: Bláha V, ed. Nutritive and Metabolic Support in Critical Cases and Organ Failure. Praha: Galén, 2001; 159-62.
10. Bláha M. Therapy of myeloma and other paraproteinemias by plasmapheresis. In: Sakalová A, Bláha M, Tichy M, eds. Multiple Myeloma and Paraproteinemias. Bratislava, Slovak Republic: Slovak Academic Press. 1995;121-5.
11. Molinaro R, Adam A, Lepage Y, Hammerschmidt D, Koenigbauer U, Eastlund T. Hypotensive reaction during staphylococcal A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg - bradykinin after contact activation. Transfusion 2002;42:1458-65.
12. Borberg H. Results of an open, longitudinal multicenter LDL-apheresis trial. Transf Sci 2000;20:83-94.
13. Bláha M, Zadák Z, Bláha V, Maly J et al. The importance and mutual correlation between the indicators of atheromatosis activity after LDL-apheresis. Acta Med (Hradec Králové) 2002;45:48.
14. Blessing F, Wang Y, Nagel D, Seidel D. The efficacy and safety of the new heparin-induced extracorporeal low-density lipoprotein precipitation system (Plasmat Futura) in comparison with the currently used system (Plasmat Secura). Ther Apher Dial 2004;8:33-8.
15. Blessing F, Wang Y, Walli AK, Seidel D. Heparin-induced extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease. Transf Sci 2004;30:255-66.
16. Cassens U, Baumann C, Hilamnn H et al. Circulatory arrest during PBPC apheresis in an unrelated donor. Transfusion 2003;43:736-41.
17. Bláha M, Maŝín V, Stránský P, Bláha V et al. Optimization of therapeutic procedure during LDL-apheresis - a computerized model. Transf Sci 2005;32:149-56.
18. Pták J. Immunoadsorption in the Therapy of Myasthenia Gravis (In Czech.). Praha: Galén, 2005.
19. Toepfer M, Sitter T, Burchardi C. Klinische Immunoadsorption. Dtsch Med Wochenschr 1999;124:461-5.
20. Carsten O, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG. Efficacy and safety of a new whole-blood-low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003;27:1116-22.
21. Silvestro DG, Marson P, Russo GE, Vicarioto M, Donadel C. National Survey of apheresis activity in Italy (2000). Transf Sci 2004;30:61-71.
22. Kaiser R, Geulen O, Matz B. Risk of hepatitis C after immunoadsorption. Infect Control Hosp Epidemiol 2002;23:342-3.